Pharmaceuticals Financial News

regulatory regime, a government-appointed three-member panel is mulling the idea of making commonly used cough and cold medicines, antacids, and fever-reducing drugs available 'over the counter' (OTC) at general stores. Many countries, such as Britain, the US and Australia, have well-defined guidelines for their sale and regulation. In 2022, India allowed the sale of certain drugs without a prescription as part of a new OTC drug policy. Though the Drugs Technical Advisory Board, the top advisory board on drugs, approved the policy, it never saw the light of the day.

Sun Pharmaceutical Industries, Lupin Ltd , Dr Reddy's Laboratories Ltd , Aurobindo Pharma , Cipla Ltd , Torrent Pharmaceuticals , Zydus Lifesciences have seen their stock price rise 27-133% in a year . As most of these companies trade near 52-week highs, Lupin leads the gains with Multibagger return of 133% in a year.

Godrej Group reached, the family will not compete among themselves for six years except in one business. Realty is the only business they can compete in, it has been agreed under the deal. As for other businesses, they can compete with each other after the six-year period ends, but not under the Godrej brand name, various reports said on May 2. In family settlement cases, non-complete agreements are a standard practice, in India as elsewhere. For the Godrejs, the non-compete period started on April 30.

Bank Nifty was down by -8.7(-0.02%) at 02 May 2024 10:44:56 IST.Other stocks such as Kotak Mahindra Bank hit their fresh 52 wk lows today.

News18 on Wednesday amid concerns over the rare side effects of the COVID-19 vaccine. Only seven to eight individuals out of 10 lakh who receive the Covishield vaccine face the risk of experiencing a rare side effect known as Thrombosis Thrombocytopenia Syndrome (TTS) Gangakhedkar told News18. “The risk is highest when you get the first dose.

Novo Nordisk, said on Wednesday it plans to invest around $200 million in quantum computing startups. The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

Serum Institute of India (SII), a day after AstraZeneca, which sold the vaccine in India, admitted in court that their Covid shot can cause a rare side effect. The parents are hopeful of justice after the AstraZeneca's admission surfaced. The pharmaceutical giant is being sued in a class-action suit over claims that its Covid-19 vaccine, developed with the University of Oxford, caused death and serious injury, including TTS — thrombosis with thrombocytopenia syndrome — a serious adverse event that causes blood clots and a low blood platelet count. Venugopalan Govindan, father of Karunya, who died after taking the vaccine, said the admission by AstraZeneca is «too late» and has come after so many lives have been lost. «AstraZeneca and SII should have stopped the manufacture and supply of these vaccines when 15 European countries either suspended or age-limited these due to deaths from blood clots that happened in March 2021, within a couple of months of the rollout of the vaccine itself.»

The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters such as Ozempic and Victoza. The crackdown is the latest assault against what the agency regards as drugmakers’ patent ploys intended to stall generic competition. At issue is what is called the Orange Book, a document published by the Food and Drug Administration that lists patents relevant to brand-name pharmaceuticals.

Stocks that traded heavily or had substantial price changes on Monday: Tesla, Domino’s Pizza rise; AMC Entertainment, SoFi Technologies fall

Shares of Aurobindo Pharma Ltd.(up 1.82 per cent), Zydus Lifesciences Ltd.(up 1.66 per cent), Laurus Labs Ltd.(up 1.56 per cent), Abbott India Ltd.(up 1.53 per cent) and Lupin Ltd.(up 1.34 per cent) ended the day as top gainers in the pack.

Alkem Laboratories Ltd.(up 1.99 per cent), Zydus Lifesciences Ltd.(up 1.87 per cent), Sun Pharmaceutical Industries Ltd.(up 1.24 per cent), Lupin Ltd.(up 1.13 per cent) and Aurobindo Pharma Ltd.(up 1.03 per cent) were among the top gainers.

India's dependence on Chinese industrial goods like telecom, machinery and electronics, Beijing's share in New Delhi's imports of such goods rose to 30 per cent from 21 per cent in the last 15 years, a report said. According to the report by the economic think tank Global Trade Research Initiative (GTRI), the growing trade deficit with China is a cause of concern, and the strategic implications of this dependency are profound, affecting not only economic but also national security dimensions. From 2019 to 2024, India's exports to China have stagnated at around USD 16 billion annually, while imports from China have surged from USD 70.3 billion in 2018-19 to over USD 101 billion in 2023-24, resulting in a cumulative trade deficit exceeding USD 387 billion over five years. The Indian government and industries must evaluate and potentially recalibrate their import strategies, fostering more diversified and resilient supply chains, GTRI founder Ajay Srivastava said.

Executive search firms say about 30-50% of their CXO searches in the last six to 18 months have been looking at potential global candidates, up from about 10-15% a few years ago. There is a preference for returning Indians fuelled by a push from companies and boards amid an increasing need for professionals with a keen knowledge and understanding of global markets. An acute demandsupply mismatch in the leadership talent market and the need to hire for specialist roles in high-tech manufacturing, automotive, electric vehicles (EVs), pharmaceuticals, chemicals, hardcore product engineering and services industries have underscored the trend, said experts. “About one in three leadership searches that we conduct today are global, not limited to India, reaching out to people in Singapore, US, Canada, London, and Middle East, showing the rising demand for the global talent pool of Indians,” said Puneet Pratap Singh, partner-in-charge at Heidrick & Struggles India.

Evonik India Research Hub (EIRH), in Thane on April 23, 2024. The company said the inauguration ceremony was attended by the Consul General of the Federal Republic of Germany in Mumbai — Dr. Achim Fabig. Evonik India’s new office, spread across 100,000 square feet, will serve as a hub for Evonik's operations in India, providing an inspiring environment for employees to collaborate, innovate, and drive growth, the company said in a statement. Evonik currently employs approximately 850 employees in India in its three entities. The EIRH is a crucial hub for developing new products and technologies catering to the needs of the Indian market and creating products tailored to Indian customers' specific requirements. EIRH will also be a global support center for formulation development in pharmaceuticals, nutraceuticals, and the food industry, the company said.

financial services — in employing women in key managerial personnel (KMP) roles across the top 200 BSE-listed companies. While female KMPs in the financial services sector were all professional leaders, in pharma, they were promoters, according to data from FY23 collated for ET by executive search firm EMA Partners India. However, Indian companies continue to struggle to have a better gender balance when it comes to KMPs. According to the Companies Act, KMPs are the CEOs or managing directors, chief financial officers, company secretaries and wholetime directors.

NPPA) expert committee is studying the existing price regulations prevalent in other countries to come out with a «unique» pricing mechanism for manufacturers of medical devices in India, people in the know told ET. At present there is no separate pricing framework followed for medical devices. The government has been using the same framework which was created for drugs in case they want to regulate the price of any medical device. Earlier, it had regulated the prices of stents and knee implants under the Drug Price Control Order. The NPPA along with officials in the department of pharmaceuticals (DoP), India's drug regulatory authority, and others have been deliberating on the issue and studying the pricing framework followed by other countries.

The surging dollar has hurt stocks outside the US but one group at least stands to gain: companies that export to the world’s largest economy.

Nestlé India and Dr. Reddy’s Laboratories Ltd on Thursday announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to consumers in India and other agreed territories.

companies making exaggerated claims about their wellness products. These are indeed welcome developments. The Patanjali order involves a case between the Indian Medical Association (IMA) and the Union of India where the former alleged that Ramdev had made statements labelling allopathy as “stupid and bankrupt science".

Syngene International share price have remained volatile in the recent past. The concerns on challenging funding conditions for US biotech that led to decreased demand for R&D services have addded to the volatility in Biocon Research arm Syngene International share prices. Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “While the fourth quarter performance came in lower than expected, the underlying driver -reduced demand for research and development services within US biotech stemming from a difficult funding environment - is well understood and already showing positive signs of recovery" Syngene International saw reported revenue from operations for the fourth quarter decline 8% year-on-year to Rs.

Biocon with a target price of Rs 340. The current market price of Biocon Ltd. is Rs 292. Biocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 34769.38 Crore) operating in Pharmaceuticals sector.